The possibilities of using a new fixed-dose combination of rosuvastatin and acetylsalicylic acid: Focus groups of patients
Остроумова О. Д., Кочетков А. И., Воеводина Н. Y., Шаронова С. С.
Рациональная фармакотерапия в кардиологии
Т. 14, Вып. 3, С. 425-433
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.20996/1819-6446-2018-14-3-425-433
Аннотация:
The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atherosclerosis - ischemic stroke, ischemic heart disease and lower-extremity arterial disease are given. The current principles of drug therapy are considered from the point of view of improving the prognosis and eliminating ischemia. The basic positions of International and Russian clinical recommendations on the management of patients with the presence of certain clinical manifestations of atherosclerosis are discussed. Detailed administration schemes and the preferred doses of statins and antiplatelet agents depending on the localization of atherosclerotic lesion and the severity of stenosis are described. The target blood lipids levels in the treatment with statins are given. The advantages of stati
Ключевые слова:
Acetylsalicylic acid; Atherosclerosis; Clinical recommendations; Fixed-dose combination; Ischemic heart disease; Ischemic stroke; Lower-extremity arterial disease; Rosuvastatin
acetylsalicylic acid; antithrombocytic agent; hydroxymethylglutaryl coenzyme A reductase inhibitor; Article; atherogenesis; atherosclerosis; brain ischemia; cardiovascular disease; carotid artery disease; clinical feature; coronary artery bypass surgery; coronary artery disease; disease severity; human; hyperlipidemia; ischemic heart disease; leg ischemia; lipid blood level; morbidity; mortality; percutaneous coronary intervention; prognosis; risk reduction
Язык текста: Русский
ISSN: 2225-3653
Остроумова О. Д. Ольга Дмитриевна 1968-
Кочетков А. И.
Воеводина Н. Y.
Шаронова С. С. Светлана Сергеевна 1997-
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Kochetkov A. I.
Voevodina N. Y.
Sharonova S. S. Svetlana Sergeevna 1997-
The possibilities of using a new fixed-dose combination of rosuvastatin and acetylsalicylic acid: Focus groups of patients
Текст визуальный непосредственный
Рациональная фармакотерапия в кардиологии
Столичная издательская компания
Т. 14, Вып. 3 С. 425-433
2018
Статья
Acetylsalicylic acid Atherosclerosis Clinical recommendations Fixed-dose combination Ischemic heart disease Ischemic stroke Lower-extremity arterial disease Rosuvastatin
acetylsalicylic acid antithrombocytic agent hydroxymethylglutaryl coenzyme A reductase inhibitor Article atherogenesis atherosclerosis brain ischemia cardiovascular disease carotid artery disease clinical feature coronary artery bypass surgery coronary artery disease disease severity human hyperlipidemia ischemic heart disease leg ischemia lipid blood level morbidity mortality percutaneous coronary intervention prognosis risk reduction
The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atherosclerosis - ischemic stroke, ischemic heart disease and lower-extremity arterial disease are given. The current principles of drug therapy are considered from the point of view of improving the prognosis and eliminating ischemia. The basic positions of International and Russian clinical recommendations on the management of patients with the presence of certain clinical manifestations of atherosclerosis are discussed. Detailed administration schemes and the preferred doses of statins and antiplatelet agents depending on the localization of atherosclerotic lesion and the severity of stenosis are described. The target blood lipids levels in the treatment with statins are given. The advantages of stati